Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
amlodipine + telmisartan + rosuvastatin
- Development stage
- Unknown
- Lead developer
- Addpharma
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
AD-231 is a fixed-dose combination (FDC) therapy developed by Addpharma for the management of patients with concurrent hypertension and dyslipidemia. It consists of three active pharmaceutical ingredients: amlodipine, a dihydropyridine calcium channel blocker (CCB); telmisartan, an angiotensin II receptor blocker (ARB); and rosuvastatin, an HMG-CoA reductase inhibitor (statin). By combining these three agents into a single tablet, AD-231 aims to improve patient adherence to complex cardiovascular treatment regimens. The combination effectively lowers blood pressure through two distinct mechanisms—calcium channel blockade and renin-angiotensin system inhibition—while simultaneously reducing LDL cholesterol levels. AD-231 was developed in South Korea and is marketed by Yuhan under the brand name Duowell Plus.
- Brand names
- Duowell Plus
- Other names
- amlodipine + telmisartan + rosuvastatintelmisartan + amlodipine + rosuvastatin
02
Targets
PPARG (Peroxisome proliferator-activated receptor gamma)CACNA1C (Voltage-dependent L-type calcium channel subunit alpha-1C)AGTR1 (Angiotensin II Type-1 receptor)CACNA1D (Voltage-dependent L-type calcium channel subunit alpha-1D)HMGCR (3-hydroxy-3-methylglutaryl-coenzyme A reductase)
Beyond the preview
Go deeper on amlodipine + telmisartan + rosuvastatin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on amlodipine + telmisartan + rosuvastatin.